Ref ID: 18400
Author:
Anna Stanziola, Emanuela Carpentieri, Carolina Vitale, Manuela Pitassi,
Nunzia Sorrentino, Matteo Sofia.
Author address:
Department of Lung Diseases, University
Federico II Naples, Naples, Italy
Full conference title:
European Respiratory Congress
Abstract:
Allergic bronchopulmonary aspergillosis (ABPA) in immunocompetent patients
may represent a cause of severe, difficult to control asthma associated with recurrent
exacerbations and dependence to systemic steroid.We describe of 5 F patients,
age mean 62.6 y (range 50 – 74) with ABPA who were treated with combined anti-
IgE omalizumab and Voriconazole.They have skin prick test positive to different
pollens (Parietaria, grass) and perennial allergens such as mites and Aspergillus
fumigatus, but also high levels of total (732±228 UI/mL) and specific IgE towards
Aspergillus f. (>25 Ku/L) in the absence of invasive aspergillosis. Their treatment
consisted of ICS and LABA daily and orally steroids during exacerbations (about
6-7/y).
All of the patients have CT- rhinosinusitis and 1of 5 pts has radiological signs
of bronchiectasis. The PFR showed obstructive ventilatory pattern with FEV1%
th = 66±6; FVC% th = 77±11 and ACT score was 17.Voriconazole 200mg bid
was admistrated for two months before treatment with biological therapy with
Omalizumab even if the serum levels of galactomannan were negative. 3 months
later treatment with voriconazole, the specific Aspergillus f. IgE levels returned
normal.
After 1 year of treatment with Omalizumab, the exacerbations rate (8 vs 3) and the
ACT score were reduced (21 vs 17); FEV1% th 75 improved and total IgE levels
were lower (363±173 UI/mL). Second year of treatment: the specific aspergillus
IgE levels returned to be high but no exacerbation was registred and ACT remained
stable.In APBA patients with severe allergic asthma the combined therapy with
omalizumab and voriconazole in burst might offer a longer and safer approach in
this setting.
Abstract Number: P276
Conference Year: 2011
Link to conference website: http://www.ers-education.org/ersMade/abstract_print_11/files/Abstract_book_2011.pdf
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a